California State Teachers Retirement System lessened its stake in shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 3.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 69,576 shares of the company’s stock after selling 2,240 shares during the period. California State Teachers Retirement System owned approximately 0.17% of Pacira Pharmaceuticals worth $3,319,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Northern Trust Corp increased its holdings in shares of Pacira Pharmaceuticals by 9.1% in the 2nd quarter. Northern Trust Corp now owns 505,529 shares of the company’s stock worth $24,114,000 after purchasing an additional 42,289 shares in the last quarter. State Street Corp boosted its stake in shares of Pacira Pharmaceuticals by 1.0% in the 2nd quarter. State Street Corp now owns 1,118,083 shares of the company’s stock worth $53,340,000 after buying an additional 10,727 shares during the last quarter. Baillie Gifford & Co. boosted its stake in shares of Pacira Pharmaceuticals by 40.9% in the 2nd quarter. Baillie Gifford & Co. now owns 301,000 shares of the company’s stock worth $14,358,000 after buying an additional 87,400 shares during the last quarter. Stephens Investment Management Group LLC boosted its stake in shares of Pacira Pharmaceuticals by 5.1% in the 2nd quarter. Stephens Investment Management Group LLC now owns 942,969 shares of the company’s stock worth $44,980,000 after buying an additional 45,514 shares during the last quarter. Finally, TIAA CREF Investment Management LLC boosted its stake in shares of Pacira Pharmaceuticals by 40.4% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 191,224 shares of the company’s stock worth $9,121,000 after buying an additional 55,057 shares during the last quarter.

A number of equities analysts have recently issued reports on PCRX shares. Zacks Investment Research downgraded Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, October 9th. Canaccord Genuity restated a “buy” rating and issued a $44.00 price target (down from $48.00) on shares of Pacira Pharmaceuticals in a research note on Sunday, October 1st. CIBC started coverage on Pacira Pharmaceuticals in a research note on Thursday, September 7th. They issued a “market perform” rating on the stock. Wedbush restated an “outperform” rating and issued a $87.00 price target on shares of Pacira Pharmaceuticals in a research note on Wednesday, October 25th. Finally, Needham & Company LLC restated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Tuesday, September 26th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $50.43.

In other news, CAO Kristen Marie Williams sold 3,461 shares of the business’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total value of $127,191.75. Following the transaction, the chief accounting officer now directly owns 21,312 shares in the company, valued at $783,216. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David M. Stack sold 28,885 shares of Pacira Pharmaceuticals stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $36.37, for a total value of $1,050,547.45. Following the completion of the sale, the chief executive officer now directly owns 159,164 shares in the company, valued at $5,788,794.68. The disclosure for this sale can be found here. Insiders sold 33,390 shares of company stock worth $1,215,480 over the last 90 days. Company insiders own 6.60% of the company’s stock.

Pacira Pharmaceuticals, Inc. (PCRX) opened at $35.05 on Wednesday. Pacira Pharmaceuticals, Inc. has a 52-week low of $29.81 and a 52-week high of $58.95. The company has a current ratio of 7.84, a quick ratio of 7.26 and a debt-to-equity ratio of 1.03.

ILLEGAL ACTIVITY WARNING: “California State Teachers Retirement System Has $3.32 Million Position in Pacira Pharmaceuticals, Inc. (PCRX)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/11/08/california-state-teachers-retirement-system-has-3-32-million-position-in-pacira-pharmaceuticals-inc-pcrx.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.